Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Lymphoma

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 259 articles:
HTML format
Text format



Single Articles


    May 2017
  1. NAGAI H, Shimomura T, Takeuchi M, Hanada S, et al
    Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma.
    Leuk Lymphoma. 2017 May 16:1-7. doi: 10.1080/10428194.2017.1319054.
    PubMed     Text format     Abstract available


  2. XIAO X, Huang H, Chen J, Jiang Y, et al
    Haploidentical hematopoietic stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with refractory or relapsed aggressive non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 May 16:1-5. doi: 10.1080/10428194.2017.1317096.
    PubMed     Text format    


  3. WAGNER-JOHNSTON ND, Lensing S, Noy A, Ratner L, et al
    High frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: prospective multicenter trial of the AIDS malignancies consortium (AMC 064).
    Leuk Lymphoma. 2017 May 16:1-4. doi: 10.1080/10428194.2017.1317095.
    PubMed     Text format     Abstract available


  4. DYSHLOVOY SA, Rast S, Hauschild J, Otte K, et al
    Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells.
    Leuk Lymphoma. 2017 May 16:1-11. doi: 10.1080/10428194.2017.1317091.
    PubMed     Text format     Abstract available


  5. SUN HL, Atenafu EG, Tsang R, Kukreti V, et al
    Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.
    Leuk Lymphoma. 2017 May 15:1-8. doi: 10.1080/10428194.2017.1307980.
    PubMed     Text format     Abstract available


  6. SKAMENE T, Crump M, Savage KJ, Reiman T, et al
    Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
    Leuk Lymphoma. 2017 May 15:1-9. doi: 10.1080/10428194.2017.1312379.
    PubMed     Text format     Abstract available


  7. GUSS ZD, Madkhali A, Chen Q, Zhang Y, et al
    Intensity-modulated involved-site radiation therapy for non-Hodgkin lymphoma of the head and neck.
    Leuk Lymphoma. 2017 May 9:1-3. doi: 10.1080/10428194.2017.1312388.
    PubMed     Text format    


  8. HO JC, Dabaja BS, Milgrom SA, Smith GL, et al
    Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 May 9:1-12. doi: 10.1080/10428194.2017.1312381.
    PubMed     Text format     Abstract available


  9. FALAY O, Ozturk E, Bolukbasi Y, Gumus T, et al
    Use of fluorodeoxyglucose positron emission tomography for diagnosis of bleomycin-induced pneumonitis in Hodgkin lymphoma.
    Leuk Lymphoma. 2017;58:1114-1122.
    PubMed     Text format     Abstract available


    April 2017
  10. DRENNAN AC, Rui L
    HiJAKing the epigenome in leukemia and lymphoma.
    Leuk Lymphoma. 2017 Apr 12:1-8. doi: 10.1080/10428194.2017.1312370.
    PubMed     Text format     Abstract available


  11. GUPTA NK, Wang CC, Mannis GN, Yu JJ, et al
    Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.
    Leuk Lymphoma. 2017 Apr 10:1-4. doi: 10.1080/10428194.2017.1312374.
    PubMed     Text format    


  12. VALDEZ BC, Li Y, Murray D, Liu Y, et al
    The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
    Leuk Lymphoma. 2017 Apr 10:1-12. doi: 10.1080/10428194.2017.1306647.
    PubMed     Text format     Abstract available


  13. WASHIO K, Oka T, Abdalkader L, Muraoka M, et al
    Gene expression analysis of hypersensitivity to mosquito bite, chronic active EBV infection and NK/T-lymphoma/leukemia.
    Leuk Lymphoma. 2017 Apr 3:1-12. doi: 10.1080/10428194.2017.1304762.
    PubMed     Text format     Abstract available


  14. BARRACLOUGH AA, Cheah CY
    Three different hematologists, three different answers: how should we treat concurrent systemic and central nervous system lymphoma?
    Leuk Lymphoma. 2017 Apr 3:1-3. doi: 10.1080/10428194.2017.1307364.
    PubMed     Text format    


    March 2017
  15. WU SC, Chapman JR, Vega F, Abrahams N, et al
    Hepatosplenic T-cell lymphoma associated with membranoproliferative glomerulonephritis.
    Leuk Lymphoma. 2017 Mar 28:1-4. doi: 10.1080/10428194.2017.1307358.
    PubMed     Text format    


  16. EL CHEIKH J, Massoud R, Haffar B, Fares E, et al
    Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.
    Leuk Lymphoma. 2017 Mar 28:1-3. doi: 10.1080/10428194.2017.1307362.
    PubMed     Text format    


  17. KOSTOS L, Chai KL, Tam CS, Bazargan A, et al
    The positive effect of deferasirox on erythropoiesis in a patient with a dual diagnosis of myelofibrosis and diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Mar 23:1-4. doi: 10.1080/10428194.2017.1281414.
    PubMed     Text format    


  18. YOON KA, Kim MK, Eom HS, Lee H, et al
    Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2017 Mar 22:1-6. doi: 10.1080/10428194.2017.1300893.
    PubMed     Text format     Abstract available


  19. BORCHMANN S, von Tresckow B
    Novel agents in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Mar 20:1-12. doi: 10.1080/10428194.2017.1300898.
    PubMed     Text format     Abstract available


  20. CEDERLEUF H, Hjort Jakobsen L, Ellin F, de Nully Brown P, et al
    Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study.
    Leuk Lymphoma. 2017 Mar 20:1-9. doi: 10.1080/10428194.2017.1300888.
    PubMed     Text format     Abstract available


  21. CHEN Y, Zheng X, Chen B, Yang X, et al
    The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Mar 17:1-7. doi: 10.1080/10428194.2017.1300894.
    PubMed     Text format     Abstract available


  22. PHAM AQ, Broski SM, Habermann TM, Jevremovic D, et al
    Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue.
    Leuk Lymphoma. 2017 Mar 14:1-7. doi: 10.1080/10428194.2017.1300891.
    PubMed     Text format     Abstract available


  23. ALBANO D, Bosio G, Giubbini R, Bertagna F, et al
    18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation.
    Leuk Lymphoma. 2017 Mar 7:1-7. doi: 10.1080/10428194.2017.1298754.
    PubMed     Text format     Abstract available


  24. SHUSTOV A, Coiffier B, Horwitz S, Sokol L, et al
    Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.
    Leuk Lymphoma. 2017 Mar 7:1-7. doi: 10.1080/10428194.2017.1295143.
    PubMed     Text format     Abstract available


  25. NANNI C, Cottereau AS, Lopci E, Bodet-Milin C, et al
    Report of the 6th International Workshop on PET in lymphoma.
    Leuk Lymphoma. 2017 Mar 7:1-6. doi: 10.1080/10428194.2017.1298752.
    PubMed     Text format     Abstract available


  26. AKYUZ N, Albert-Konetzny N, Pott C, Callet-Bauchu E, et al
    MALT1 sequencing analyses in marginal zone B-cell lymphomas reveal mutations in the translocated MALT1 allele in an IGH-MALT1-positive MALT lymphoma.
    Leuk Lymphoma. 2017 Mar 2:1-5. doi: 10.1080/10428194.2017.1296144.
    PubMed     Text format    


    February 2017
  27. LI XY, Geng LY, Zhou XX, Wei N, et al
    Kruppel-like factor 4 contributes to the pathogenesis of mantle cell lymphoma.
    Leuk Lymphoma. 2017 Feb 28:1-10. doi: 10.1080/10428194.2017.1292354.
    PubMed     Text format     Abstract available


  28. AKASAKA T, Lee YF, Novak AJ, Honjo G, et al
    Clinical, histopathological, and molecular features of mucosa-associated lymphoid tissue (MALT) lymphoma carrying the t(X;14) (p11;q32)/GPR34-immunoglobulin heavy chain gene.
    Leuk Lymphoma. 2017 Feb 28:1-4. doi: 10.1080/10428194.2017.1289525.
    PubMed     Text format    


  29. COHEN JB, Maddocks KJ, Huang Y, Christian BA, et al
    A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
    Leuk Lymphoma. 2017 Feb 20:1-2. doi: 10.1080/10428194.2017.1289527.
    PubMed     Text format    


  30. WANG L, Luo L, Gao Z, Liu SF, et al
    The diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: a meta-analysis.
    Leuk Lymphoma. 2017 Feb 20:1-8. doi: 10.1080/10428194.2017.1289523.
    PubMed     Text format     Abstract available


  31. DING X, Chi J, Yang X, Hao J, et al
    Cucurbitacin B synergistically enhances the apoptosis-inducing effect of arsenic trioxide by inhibiting STAT3 phosphorylation in lymphoma Ramos cells.
    Leuk Lymphoma. 2017 Feb 20:1-13. doi: 10.1080/10428194.2017.1289521.
    PubMed     Text format     Abstract available


  32. SCHMIDT-HANSEN M, Berendse S, Marafioti T, McNamara C, et al
    Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review.
    Leuk Lymphoma. 2017 Feb 9:1-16. doi: 10.1080/10428194.2017.1287364.
    PubMed     Text format     Abstract available


  33. RAJYAGURU DJ, Bhaskar C, Borgert AJ, Smith A, et al
    Intravascular large B-cell lymphoma in the United States (US): a population-based study using Surveillance, Epidemiology, and End Results program and National Cancer Database.
    Leuk Lymphoma. 2017 Feb 9:1-9. doi: 10.1080/10428194.2017.1287363.
    PubMed     Text format     Abstract available


  34. NIJLAND M, Jansen A, Doorduijn JK, Enting RH, et al
    Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma.
    Leuk Lymphoma. 2017 Feb 6:1-6. doi: 10.1080/10428194.2017.1285026.
    PubMed     Text format     Abstract available


    January 2017
  35. KAHL BS, Dreyling M, Gordon LI, Quintanilla-Martinez L, et al
    Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.
    Leuk Lymphoma. 2017 Jan 31:1-12. doi: 10.1080/10428194.2017.1283036.
    PubMed     Text format     Abstract available


  36. AMIOT A, Jooste V, Gagniere C, Levy M, et al
    Second primary malignancies in patients treated for gastric mucosa-associated lymphoid tissue lymphoma.
    Leuk Lymphoma. 2017 Jan 31:1-11. doi: 10.1080/10428194.2017.1283033.
    PubMed     Text format     Abstract available


  37. HOLKOVA B, Yazbeck V, Kmieciak M, Bose P, et al
    A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
    Leuk Lymphoma. 2017 Jan 19:1-9. doi: 10.1080/10428194.2016.1276287.
    PubMed     Text format     Abstract available


  38. CUBILLOS-ZAPATA C, Cordoba R, Avendano-Ortiz J, Lopez-Collazo E, et al
    Thalidomide analog CC-122 induces a refractory state in monocytes from patients with diffuse large B cell lymphoma.
    Leuk Lymphoma. 2017 Jan 16:1-6. doi: 10.1080/10428194.2016.1272686.
    PubMed     Text format    


  39. DHANAPAL V, Gunasekara M, Lianwea C, Marcus R, et al
    Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.
    Leuk Lymphoma. 2017 Jan 16:1-9. doi: 10.1080/10428194.2016.1276288.
    PubMed     Text format     Abstract available


  40. SKARBNIK AP, Ma E, Lafeuille MH, Fortier J, et al
    Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.
    Leuk Lymphoma. 2017 Jan 16:1-8. doi: 10.1080/10428194.2016.1272688.
    PubMed     Text format    


  41. RAVI KUMAR AS, Tam C, Hofman MS
    FDG PET in follicular lymphoma: more than a staging test?
    Leuk Lymphoma. 2017 Jan 16:1-6. doi: 10.1080/10428194.2016.1272691.
    PubMed     Text format    


  42. BIRSEN R, Boutboul D, Crestani B, Seguin-Givelet A, et al
    Talc pleurodesis allows long-term remission in HIV-unrelated Human Herpesvirus 8-associated primary effusion lymphoma.
    Leuk Lymphoma. 2017 Jan 13:1-9. doi: 10.1080/10428194.2016.1271947.
    PubMed     Text format    


  43. WANG T, Xu P, Wang F, Zhou D, et al
    Effects of digoxin on cell cycle, apoptosis and NF-kappaB pathway in Burkitt's lymphoma cells and animal model.
    Leuk Lymphoma. 2017 Jan 13:1-16. doi: 10.1080/10428194.2016.1256480.
    PubMed     Text format     Abstract available


    December 2016
  44. MORRISON VA, Weller EA, Habermann TM, Li S, et al
    Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  45. SEELIG DM, Ito D, Forster CL, Yoon UA, et al
    Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  46. GLEESON M, Hawkes EA, Peckitt C, Wotherspoon A, et al
    Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  47. STAIGER AM, Duppel J, Dengler MA, van der Kuip H, et al
    An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  48. BHETHANABHOTLA S, Jain S, Kapoor G, Mahajan A, et al
    Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  49. SHANMUGAM V, Dorfman DM
    An unusual case of chronic lymphocytic leukemia/small lymphocytic lymphoma with nodular morphology.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    November 2016
  50. VOGT N, Dai B, Erdmann T, Berdel WE, et al
    The molecular pathogenesis of mantle cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  51. HJALGRIM H, Rostgaard K
    Socio-economic risk patterns in Hodgkin lymphoma: not more, but new studies are warranted.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  52. OLSZEWSKI AJ
    Blunt tools, burning questions: using cancer registry data to study relapsed/refractory lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  53. WASTERLID T, Nordstrom L, Freiburghaus C, Pedersen M, et al
    Frequency and clinical implications of SOX11 expression in Burkitt lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  54. BARTLETT NL, Smith MR, Siddiqi T, Advani RH, et al
    Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  55. LI T, Liu ZG, Liang PQ, Wang HT, et al
    Can body mass index predict the outcome of diffuse large B-cell lymphoma? A single-center retrospective study in China.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  56. HUSSAINI MO, Rehman A, Chavez JC, Pinilla-Ibarz J, et al
    EBV-positive Richter's syndrome with laboratory features of Burkitt's lymphoma, in Ibrutinib-treated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  57. BOND DA, Huang Y, Ruppert AS, Walker AR, et al
    Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  58. RAI A, Nastoupil LJ, Williams JN, Lipscomb J, et al
    Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  59. SHAO D, Gao Q, Liang CH, Wang SX, et al
    Discussion of 18F-FDG PET/CT imaging characteristics and diagnostic values of angioimmunoblastic T-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  60. CHOE H, Martin P
    Frontline autologous stem cell transplant for high-risk follicular lymphoma: forever elusive?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  61. FINNES HD, Chaffee KG, Call TG, Ding W, et al
    Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  62. MOSKOWITZ AJ, Horwitz SM
    Targeting histone deacetylases in T-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  63. MOCCIA AA, Zucca E, Ghielmini M
    Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  64. WIRTH A, Dabaja B
    Optimizing treatment for nasal NK T-cell lymphoma.
    Leuk Lymphoma. 2016;57:2487-8.
    PubMed     Text format    


    October 2016
  65. VILLASBOAS JC, Ansell S
    Glancing at the complex biology of T-cells through the microenvironment of Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  66. PHILLIPS AA
    Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  67. ABRAMSON JS
    Bone marrow biopsies for staging of diffuse large B-cell lymphoma: are we looking too closely?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  68. GOLDSCHMIDT N, Darawshy F, Kleinstern G, Slyusarevsky E, et al
    The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  69. SEFTEL MD, Kuruvilla J, Kouroukis T, Banerji V, et al
    The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  70. LOHNEIS P, Wienert S, Klauschen F, Anagnostopoulos I, et al
    Fibrosis in low-grade follicular lymphoma - a link to the TH2 immune reaction.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  71. BENADIBA J, Rosilio C, Nebout M, Heimeroth V, et al
    Iron chelation: an adjuvant therapy to target metabolism, growth and survival of murine PTEN-deficient T lymphoma and human T lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  72. SVENDSEN P, Shekhrajka N, Nielsen KL, Vestergaard P, et al
    R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  73. ALONSO-ALVAREZ S, Vidriales MB, Caballero MD, Blanco O, et al
    The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  74. PELED JU, Jenq RR
    Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  75. TAJIMA K, Takahashi N, Ishizawa K, Murai K, et al
    Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  76. FORD RR, Ford RW, O'Neal M, Kahl BS, et al
    Investigator and independent review committee exploratory assessment and verification of tumor response in a non-Hodgkin lymphoma study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  77. CARR R, Ozdag H, Tekin N, Morris T, et al
    The effect of biological heterogeneity on R-CHOP treatment outcome in diffuse large B-cell lymphoma across five international regions.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  78. MOON SH, Lee AY, Kim WS, Kim SJ, et al
    Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  79. ALKHATIB Y, Abdel Rahman Z, Kuriakose P
    Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    September 2016
  80. GASCOYNE DM, Banham AH
    The significance of FOXP1 in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  81. XIAO DY, Luo S, O'Brian K, Liu W, et al
    Weight change trends and overall survival in United States veterans with follicular lymphoma treated with chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  82. PROCHAZKA V, Papajik T, Janikova A, Belada D, et al
    Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  83. DANESE MD, Griffiths RI, Gleeson ML, Dalvi T, et al
    Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  84. LI DH, Zhang XY, Du C, Zhang WH, et al
    Successful treatment of extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis with MEDA chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  85. MAURYA AK, Vinayak M
    PI-103 attenuates PI3K-AKT signaling and induces apoptosis in murineT-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  86. TANRIVERDI E, Acat M, Ozgul G, Abbasli K, et al
    Primary pulmonary lymphoma: four different and unusual radiologic and clinical manifestations.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  87. TOKUNAGA M, Uto H, Takeuchi S, Nakano N, et al
    Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  88. DE LA FUENTE MI, Haggiagi A, Moul A, Young RJ, et al
    Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  89. PAPAGEORGIOU SG, Kontos CK, Foukas PG, Panopoulou E, et al
    BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era.
    Leuk Lymphoma. 2016;57:2199-203.
    PubMed     Text format    


    August 2016
  90. LEVINE H, Leiba M, Bar Zeev Y, Keinan-Boker L, et al
    Risk of Hodgkin lymphoma according to immigration status and origin: a migrant cohort study of 2.3 million Jewish Israelis.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  91. SORIGUE M, Sancho JM, Morgades M, Moreno M, et al
    Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  92. CHAN KL, van der Weyden C, Khoo C, Lade S, et al
    Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  93. LOREE JM, Cai E, Sheffield BS, Dutz JP, et al
    Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  94. SONG Z, Wang H, Zhang H, Zhao K, et al
    Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  95. WONG-SEFIDAN I, Byrtek M, Zhou X, Friedberg JW, et al
    [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  96. MAGNANO L, Martinez A, Carreras J, Martinez-Trillos A, et al
    T-cell subsets in lymph nodes identify a subgroup of follicular lymphoma patients with favorable outcome.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  97. GURTH M, Bernard V, Bernd HW, Schemme J, et al
    Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  98. KANEMASA Y, Shimoyama T, Sasaki Y, Tamura M, et al
    The impacts of initial and relative dose intensity of R-CHOP on outcomes of elderly patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  99. OLSZEWSKI AJ
    Formulating a novel prognostic index for diffuse large B-cell lymphoma: T cells break the SILence.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  100. KAMPERS J, Orjuela-Grimm M, Schober T, Schulz TF, et al
    Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  101. KOLDEHOFF M, Ross SR, Duhrsen U, Beelen DW, et al
    Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  102. ASLAN A, Aras T, Ozdemir E
    Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  103. LE GUENNEC L, Maisonobe T, Choquet S, Massein A, et al
    Neurolymphomatosis as a relapse of primary cerebral nervous system lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  104. PARIKH RR, Yahalom J
    Older patients with early-stage diffuse large B-cell lymphoma: the role of consolidation radiotherapy after chemoimmunotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    July 2016
  105. GALANINA N, Jasielec J, Peace D, Smith SM, et al
    Ofatumumab monotherapy in relapsed/refractory diffuse large B-cell non-Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  106. YAMANAKA R, Morii K, Shinbo Y, Sano M, et al
    Late relapse of primary central nervous system lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  107. BARZENJE DA, Holte H, Fossa A, Ghanima W, et al
    Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  108. DANILOV AV, Li H, Press OW, Shapira I, et al
    Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  109. BURBURY KL, Alexander M, Westerman DA
    Risk of thromboembolism with lymphoma: myth or reality?
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    June 2016
  110. HASNI MS, Berglund M, Yakimchuk K, Guan J, et al
    Estrogen receptor beta1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  111. BRAMMER JE, Khouri I, Marin D, Ledesma C, et al
    Stem cell transplantation outcomes in lymphoblastic lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  112. ECONOMIDES MP, Mahale P, Turturro F, Hosry J, et al
    Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  113. MOCCIA AA, Hitz F, Hoskins P, Klasa R, et al
    Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  114. TRAVERSE-GLEHEN A, Verney A, Gazzo S, Jallades L, et al
    Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  115. KOSTAKOGLU L, Goy A, Martinelli G, Caballero D, et al
    FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  116. SON CH, Chiu BC, Koshy M
    Patterns of care and survival outcomes examining radiation therapy for advanced Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  117. BOLAND PJ, Hegerova LT, Williams SJ, McKenna RW, et al
    Successful treatment of two cases of classical Hodgkin lymphoma-associated hemophagocytic lymphohistiocyosis with R-CEPP.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  118. MOHANTY S, Mohanty A, Sandoval N, Tran T, et al
    Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  119. TOMITA N, Suzuki T, Miyashita K, Yamamoto W, et al
    The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  120. SEO JY, Hong J, Chun K, Jeong J, et al
    Prognostic significance of PCR-based molecular staging in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  121. HAMADAH AM, Thanarajasingam G, Gharaibeh KA, Finnes HD, et al
    Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  122. LUO H, Schmidt JA, Lee YS, Oltz EM, et al
    Targeted epigenetic repression of a lymphoma oncogene by sequence-specific histone modifiers induces apoptosis in DLBCL.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  123. UMINO K, Fujiwara SI, Ito S, Mashima K, et al
    Serum soluble interleukin-2 receptor level at diagnosis predicts transformation in patients with follicular lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  124. MARTIN P, Martinez-Velasquez J, Coronado MJ, Krsnik I, et al
    Association of DDX58 177 C > T polymorphism with decreased risk of Epstein-Barr virus-related nodular sclerosis classical Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  125. BORG IH, Bendtsen MD, Bogsted M, Madsen J, et al
    Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  126. BAETZ T, Chen BE, Couban S, Tom Kouroukis C, et al
    Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  127. ALDERUCCIO JP, Amarapurkar P, Chapman JR, Vega F, et al
    Characteristics and outcomes of lymphoblastic lymphoma - the University of Miami experience.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  128. ZINZANI PL, Rigacci L, Cox MC, Devizzi L, et al
    The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    May 2016
  129. BROCKELMANN PJ, Borchmann P, Engert A
    Current and future immunotherapeutic approaches in Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  130. ISIDORI A, Christofides A, Visani G
    Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  131. ITONAGA H, Taguchi J, Taguchi M, Taniguchi H, et al
    Adult T-cell leukemia/lymphoma in donor cells responding to second allogeneic hematopoietic stem cell transplantation using unrelated cord blood: the Nagasaki Transplant Group experience.
    Leuk Lymphoma. 2016.
    PubMed     Text format    



  132. Hadife, N., Nemos, C., Frippiat, J.-P., et al. Interleukin-24 mediates apoptosis in human B-cells through early activation of cell cycle arrest followed by late induction of the mitochondrial apoptosis pathway. Leuk. Lymphoma. 2013;54(3):587-597. http
    Leuk Lymphoma. 2016.
    PubMed     Text format    



  133. Wang, S.-Y., Chen, W.-L., Wang, Z.-C., et al. High expression of FAMLF is associated with clinical response in patients with de novo acute myeloid leukemia. Leuk. Lymphoma 2016. http://dx.doi.org/10.3109/10428194.2016.1160087.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  134. KATSUSHIMA H, Fukuhara N, Ichikawa S, Ota Y, et al
    Non-biased and complete case registration of lymphoid leukemia and lymphoma for five years: a first representative index of Japan from an epidemiologically stable Miyagi Prefecture.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  135. VON TRESCKOW B, Morschhauser F, Szer J, Eichenauer DA, et al
    Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  136. DUNCAN VE, Ping Z, Varambally S, Peker D, et al
    Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  137. QI S, Yahalom J, Hsu M, Chelius M, et al
    Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  138. KAMSTRUP MR, Biskup E, Manfe V, Savorani C, et al
    Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  139. SPIEGEL JY, Cheung MC, Guirguis HR, Buckstein R, et al
    Validation of the NCCN-IPI in both de novo and transformed diffuse large B cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  140. NOVELLI S, Garcia-Muret P, Mozos A, Sierra J, et al
    Total body-surface area as a new prognostic variable in mycosis fungoides and Sezary syndrome.
    Leuk Lymphoma. 2016;57:1060-6.
    PubMed     Text format     Abstract available


  141. GOEBELER ME, Bargou R
    Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Leuk Lymphoma. 2016;57:1021-32.
    PubMed     Text format     Abstract available


  142. DREXLER HG, Eberth S, Nagel S, MacLeod RA, et al
    Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
    Leuk Lymphoma. 2016;57:1015-20.
    PubMed     Text format     Abstract available


  143. FERNANDEZ SG, Miranda JJ
    Bendamustine reactivates latent Epstein-Barr virus.
    Leuk Lymphoma. 2016;57:1208-10.
    PubMed     Text format    


  144. OZTURK E, Ozbalak M, Berk S, Erdogan I, et al
    Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.
    Leuk Lymphoma. 2016;57:1211-4.
    PubMed     Text format    


    April 2016
  145. JOHRENS K, Trappe RU, Lenze D, Pfreundschuh M, et al
    Age and cellular composition influence overall survival in a collective of non-immunocompromised patients with EBV-positive diffuse large B-cell lymphoma from a German lymphoma center.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  146. HUDNALL SD, Meng H, Lozovatsky L, Li P, et al
    Recurrent genetic defects in classical Hodgkin lymphoma cell lines.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  147. PILORGE S, Harel S, Ribrag V, Larousserie F, et al
    Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  148. LOGHAVI S, Wang SA, Jeffrey Medeiros L, Jorgensen JL, et al
    Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  149. DANISH HH, Liu S, Jhaveri J, Flowers CR, et al
    Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sezary syndrome.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  150. LEE HJ, Dai C, Wang M, Mouhayar E, et al
    Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  151. MOCIKOVA H, Pytlik R, Sykorova A, Janikova A, et al
    Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  152. MAR N, Digiuseppe JA, Dailey ME
    Rubinstein-Taybi syndrome - a window into follicular lymphoma biology.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  153. KALPADAKIS C, Pangalis GA, Sachanas S, Rontogianni D, et al
    No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  154. YU JS, Hansen RN, Valderrama A, Carlson JJ, et al
    Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  155. MILGROM SA, Cheah CY, Pinnix CC, Smith GL, et al
    Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  156. HASSAN HM, Varney ML, Chaturvedi NK, Joshi SS, et al
    Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  157. GRATZINGER D, Jaffe ES
    Mucocutaneous ulcer: a mimic of EBV + diffuse large B cell lymphoma in the immunodeficiency setting.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  158. TAKAHASHI H, Miura K, Nakagawa M, Sugitani M, et al
    Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  159. ERDMANN T, Lenz G
    Approaching resistance to ibrutinib in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  160. SUAREZ JP, Dominguez ML, Gomez MA, Fernandez N, et al
    A unique case of in situ follicular lymphoma associated with two nonlymphoid malignancies.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    March 2016
  161. HAERY L, Mussakhan S, Waxman DJ, Gilmore TD, et al
    Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  162. TOWNSEND W, Johnson RJ, Pottinger BT, Counsell N, et al
    A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  163. PESSACH I, Petevi K, Gkirkas K, Stamouli M, et al
    Wells' syndrome with a clinicopathological correlation associated with mantle-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  164. LEHNERS N, Kramer I, Schwarzbich MA, Ho AD, et al
    Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  165. IIOKA F, Honjo G, Misaki T, Toda Y, et al
    A unique subtype of diffuse large B-cell lymphoma primarily involving the bone marrow, spleen, and liver, defined by fluorodeoxyglucose-positron emission tomography combined with computed tomography.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  166. OROFINO N, Guidotti F, Cattaneo D, Sciume M, et al
    Marked eosinophilia as initial presentation of breast implant-associated anaplastic large cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  167. SCHWARZBICH MA, Schoning T, Cremer M, Lisenko K, et al
    Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  168. TEO EC, Valdez BC, Ji J, Li Y, et al
    Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  169. CASTILLO JJ, Ghobrial IM, Treon SP
    Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  170. CHAN H, Jackson S, McLay J, Knox A, et al
    Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  171. CIAMMELLA P, Filippi AR, Simontacchi G, Buglione M, et al
    Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


    February 2016
  172. GALANINA N, Petrich A, Nabhan C
    The evolving role of lenalidomide in non-Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  173. STENSON M, Pedersen A, Hasselblom S, Nilsson-Ehle H, et al
    Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  174. KANEMASA Y, Shimoyama T, Sasaki Y, Sawada T, et al
    A convenient prognostic score consisting of the Glasgow prognostic score and serum lactate dehydrogenase predicts clinical outcome in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  175. WEI W, Sun W, Yu S, Yang Y, et al
    Butyrate production from high-fiber diet protects against lymphoma tumor.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  176. CAMUS V, Sarafan-Vasseur N, Bohers E, Dubois S, et al
    Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  177. BALZAROTTI M, Brusamolino E, Angelucci E, Carella AM, et al
    B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  178. GAC AC, Azar N, Daguindau E, Cartron G, et al
    Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  179. PAPADOPOULOS KP, Lopez-Jimenez J, Smith SE, Steinberg J, et al
    A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  180. GRIFFIN M, Fielding J, Ahmed N, Gandhi S, et al
    Remission of human immunodeficiency virus-related lymphoma in association with immune reconstitution on anti-retroviral therapy, without chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  181. ANSELL S
    How to select the frontline treatment for a patient with peripheral T-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


    January 2016

  182. Chevalier T, mueller M, mougiakakos D, et al. Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment. Leuk lymphoma. 2016. [epub ahead of print]. DOI: 10.3109/10428194.2015.1135432.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  183. MADDOCKS K, Hertlein E, Chen TL, Wagner AJ, et al
    A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  184. WHITE EC, Advani R, Hoppe RT
    2 Gy x 2 for palliative treatment of mantle cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  185. VALTOLA J, Varmavuo V, Ropponen A, Selander T, et al
    Early immune recovery after autologous transplantation in non-Hodgkin lymphoma patients: predictive factors and clinical significance.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  186. CHEAH CY, Mistry HE, Konoplev S, Fowler NH, et al
    Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  187. WOHLFARTH P, Carlstrom A, Staudinger T, Clauss S, et al
    Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  188. CASSIDY RJ, Jegadeesh N, Switchenko J, Danish H, et al
    The role of radiotherapy for patients over age 60 with diffuse large B-cell lymphoma in the rituximab era.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  189. CHEUNG MC, Prica A, Graczyk J, Buckstein R, et al
    Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  190. GRYGOROWICZ MA, Biernacka M, Bujko M, Nowak E, et al
    Human regulatory T cells suppress proliferation of B lymphoma cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  191. OH EJ, Kim EK, Yang WI, Yoon SO, et al
    Activation of the polycomb repressive complex pathway in the bone marrow resident cells of diffuse large B-cell lymphoma patients.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  192. KUCI V, Nordstrom L, Conrotto P, Ek S, et al
    SOX11 and HIG-2 are cross-regulated and affect growth in mantle cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  193. CHEVALIER N, Mueller M, Mougiakakos D, Ihorst G, et al
    Analysis of dendritic cell subpopulations in follicular lymphoma with respect to the tumor immune microenvironment.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  194. SAILLARD C, El Cheikh J, Granata A, Coso D, et al
    Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplant.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  195. AMORIM S, Fleury I, Mounier N, Harel S, et al
    Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  196. YUAN S, Yu J, Haverkos B, Su H, et al
    Remission of an extensively pre-treated relapsing/refractory ALK-positive anaplastic large cell lymphoma following metronomic therapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  197. NAM SJ, Kim S, Paik JH, Kim TM, et al
    An increase in indoleamine 2,3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone.
    Leuk Lymphoma. 2016.
    PubMed     Text format    


  198. JAKOVIC LR, Mihaljevic BS, Andjelic BM, Bogdanovic AD, et al
    Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  199. ZAIMOKU Y, Takahashi W, Iwaki N, Saito C, et al
    Human herpesvirus-8-unrelated primary effusion lymphoma of the elderly not associated with an increased serum lactate dehydrogenase level: A benign sub-group of effusion lymphoma without chemotherapy.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  200. LIU WP, Wang XP, Zheng W, Ping LY, et al
    Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  201. DONG LH, Zhang LJ, Wang WJ, Lei W, et al
    Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


  202. SORIGUE M, Junca J, Marce S, Cabezon M, et al
    The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies.
    Leuk Lymphoma. 2016;57:244-6.
    PubMed     Text format    


  203. PAPOUDOU-BAI A, Goussia A, Batistatou A, Stefanou D, et al
    The expression levels of JunB, JunD and p-c-Jun are positively correlated with tumor cell proliferation in diffuse large B-cell lymphomas.
    Leuk Lymphoma. 2016;57:143-50.
    PubMed     Text format     Abstract available


  204. TOYA T, Nannya Y, Hangaishi A, Shiseki M, et al
    Prognostic relevance of CD20 expression in peripheral T-cell lymphomas: a multi-center retrospective study.
    Leuk Lymphoma. 2016;57:961-4.
    PubMed     Text format    


  205. LEPRETRE S, Dartigeas C, Feugier P, Marty M, et al
    Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.
    Leuk Lymphoma. 2016;57:852-65.
    PubMed     Text format     Abstract available


  206. HOLKOVA B, Kmieciak M, Bose P, Yazbeck VY, et al
    Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.
    Leuk Lymphoma. 2016;57:635-43.
    PubMed     Text format     Abstract available


  207. JAMANI K, Duggan P, Neri P, Bahlis N, et al
    Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight.
    Leuk Lymphoma. 2016;57:557-62.
    PubMed     Text format     Abstract available


  208. LIPOWSKA-BHALLA G, Fagnano E, Illidge TM, Cheadle EJ, et al
    Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies.
    Leuk Lymphoma. 2016;57:1269-80.
    PubMed     Text format     Abstract available


  209. MAHALE P, Turturro F, Romaguera JE, Fowler N, et al
    The effect of different rituximab-containing chemotherapy strategies on hepatitis C viremia.
    Leuk Lymphoma. 2016;57:1487-90.
    PubMed     Text format    


  210. MIURA K, Takahashi H, Nakagawa M, Izu A, et al
    Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy.
    Leuk Lymphoma. 2016;57:1335-41.
    PubMed     Text format     Abstract available


    December 2015
  211. SUNDARARAJAN S, Chen H, Kumar A, Tus K, et al
    Donor-derived marginal zone lymphoma following reduced-intensity allogeneic peripheral blood stem cell transplant.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  212. ISONO N, Imai Y, Watanabe A, Moriya K, et al
    Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  213. KIM JH, Kim WS, Ryu K, Kim SJ, et al
    CD79B limits response of diffuse large B cell lymphoma to ibrutinib.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  214. ZENT CS, Bowen DA, Conte MJ, LaPlant BR, et al
    Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  215. VAN DEN BRAND M, van der Velden WJ, Diets IJ, Ector GI, et al
    Clinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformation.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  216. TSURUSAWA M, Watanabe T, Gosho M, Mori T, et al
    Randomized study of granulocyte colony stimulating factor for childhood B-cell non-Hodgkin lymphoma: a report from the Japanese pediatric leukemia/lymphoma study group B-NHL03 study.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  217. SASSE S, Alram M, Muller H, Smardova L, et al
    Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  218. SOHANI AR, Abramson JS
    MYC/BCL2 double-expression vs. cell-of-origin classification in diffuse large B-cell lymphoma: do we need to know both?
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  219. NATARAJ V, Mathur N, Rani L, Gupta R, et al
    Serial assessment of circulating T regulatory cells and T helper 17 cells in pediatric non-Hodgkin lymphoma: a prospective study.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  220. OCHI Y, Hiramoto N, Ono Y, Yoshioka S, et al
    Tolerability and efficacy of rituximab-containing immunochemotherapy in patients with B-cell non-Hodgkin lymphoma receiving hemodialysis.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  221. NOY A, Lensing SY, Moore PC, Gupta N, et al
    Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium.
    Leuk Lymphoma. 2015.
    PubMed     Text format    



  222. Huang PY, mactier S, armacki N, et al. Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk lymphoma 2015 nov 16. [epub ahead of print]. http://dx.doi.org/10.3109/10428194.2015.1094692.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


  223. ARCARI A, Chiappella A, Spina M, Zanlari L, et al
    Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  224. ROSCH K, Scholz M, Hasenclever D
    Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


  225. SARID N, Joffe E, Gibstein L, Avivi I, et al
    Reduced-dose ICE chemotherapy +/- rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2015.
    PubMed     Text format     Abstract available


    May 2015
  226. WIRTH A
    Putting radiotherapy into orbit.
    Leuk Lymphoma. 2015;56:1188-90.
    PubMed     Text format    


  227. SHIN SY, Lee ST, Kim HJ, Jang JH, et al
    A case of CD5-positive mature B-cell neoplasm with t(10;14)(q24;q11.2) and trisomy 12.
    Leuk Lymphoma. 2015;56:1550-1.
    PubMed     Text format    


  228. DAIFU T, Umeda K, Kouzuki K, Hamabata T, et al
    The NOD/Shi-scid/IL-2Rgamma(null) mice xenograft model recapitulates anaplastic large cell lymphoma dissemination to the bladder.
    Leuk Lymphoma. 2015;56:1542-3.
    PubMed     Text format    


  229. NIKOLAOU V, Papadavid E, Ekonomidi A, Dalamaga M, et al
    Association of clinicopathological characteristics with secondary neoplastic lymphoproliferative disorders in patients with lymphomatoid papulosis.
    Leuk Lymphoma. 2015;56:1303-7.
    PubMed     Text format     Abstract available


  230. BOHERS E, Mareschal S, Bertrand P, Viailly PJ, et al
    Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era.
    Leuk Lymphoma. 2015;56:1213-22.
    PubMed     Text format     Abstract available


  231. WASIK AM, Priebe V, Lord M, Jeppsson-Ahlberg A, et al
    Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma.
    Leuk Lymphoma. 2015;56:1425-31.
    PubMed     Text format     Abstract available


  232. BOI M, Zucca E, Inghirami G, Bertoni F, et al
    PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas.
    Leuk Lymphoma. 2015;56:1223-8.
    PubMed     Text format     Abstract available


  233. RUEDA A, Olmos D, Vicioso L, Quero C, et al
    Role of vascular endothelial growth factor C in classical Hodgkin lymphoma.
    Leuk Lymphoma. 2015;56:1286-94.
    PubMed     Text format     Abstract available


  234. ALGRIN C, Faguer S, Lemiale V, Lengline E, et al
    Outcomes after intensive care unit admission of patients with newly diagnosed lymphoma.
    Leuk Lymphoma. 2015;56:1240-5.
    PubMed     Text format     Abstract available


  235. BOULIOTIS G, Bessell EM
    Hodgkin disease (1973-2002): long-term survival and cure fractions.
    Leuk Lymphoma. 2015;56:1278-85.
    PubMed     Text format     Abstract available


  236. MCQUILLAN AD, Macdonald WB, Turner JH
    Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.
    Leuk Lymphoma. 2015;56:1271-7.
    PubMed     Text format     Abstract available


  237. HILL BT, Tubbs RR, Smith MR
    Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin.
    Leuk Lymphoma. 2015;56:1552-3.
    PubMed     Text format    


    April 2015
  238. SCHNEEWEISS M, Porpaczy E, Koch M, Jonak C, et al
    Transformed Mycosis Fungoides: Bridging to allogeneic stem cell transplantation with Brentuximab Vedotin.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


    March 2015
  239. FILANOVSKY K, Yacobi R, Vorst E, Barshack I, et al
    Second hematologic malignancies in hairy cell leukemia: report of two patients with dynamic mutations in the BRAF gene.
    Leuk Lymphoma. 2015;56:823-5.
    PubMed     Text format    


  240. BARTRAM T, Burkhardt B, Wossmann W, Seidemann K, et al
    Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin-Frankfurt-Munster Study Group.
    Leuk Lymphoma. 2015;56:814-6.
    PubMed     Text format    


  241. YAN M, Callum J, Lin Y
    Hyperhemolysis associated with marginal zone lymphoma.
    Leuk Lymphoma. 2015;56:829-31.
    PubMed     Text format    


  242. HE J, Wang F, Zhu JH, Chen W, et al
    No association between MTR rs1805087 A > G polymorphism and non-Hodgkin lymphoma susceptibility: evidence from 11 486 subjects.
    Leuk Lymphoma. 2015;56:763-7.
    PubMed     Text format     Abstract available


  243. GEORGIADI EC, Dimtsas GS, Vassilakopoulos TP, Pangalis GA, et al
    Functional p53 can modulate the relationship between E2F-1 expression and tumor kinetics in Hodgkin lymphoma.
    Leuk Lymphoma. 2015;56:748-54.
    PubMed     Text format     Abstract available


  244. ODEJIDE OO, Cronin AM, Davidoff AJ, LaCasce AS, et al
    Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients.
    Leuk Lymphoma. 2015;56:716-24.
    PubMed     Text format     Abstract available


  245. ILLIDGE T, Bouabdallah R, Chen R, Gopal AK, et al
    Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
    Leuk Lymphoma. 2015;56:703-10.
    PubMed     Text format     Abstract available


  246. TOMITA N, Takasaki H, Ishiyama Y, Kishimoto K, et al
    Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
    Leuk Lymphoma. 2015;56:725-9.
    PubMed     Text format     Abstract available


  247. SAVORANI C, Manfe V, Biskup E, Gniadecki R, et al
    Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage.
    Leuk Lymphoma. 2015;56:739-47.
    PubMed     Text format     Abstract available


  248. QUACKENBUSH RC, Horner TJ, Williams VC, Giampietro P, et al
    Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab.
    Leuk Lymphoma. 2015;56:779-81.
    PubMed     Text format    


  249. MAEGAWA S, Kuroda J, Kobayashi T, Fuchida S, et al
    Clinical manifestation and prognostic factors of 32 Japanese patients with autoimmune disease-associated diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2015;56:785-8.
    PubMed     Text format    


  250. TSAI JP, Iams WT, Greer JP, Morgan DS, et al
    Alternative intensive induction chemotherapeutic regimens in MYC expressing diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2015;56:797-800.
    PubMed     Text format    


  251. MANT S, Taylor G, Dutton D, Butler A, et al
    Development of T-cell lymphomas with an activated cytotoxic immunophenotype, including anaplastic large cell lymphomas, in patients with chronic lymphocytic leukemia: a series of six cases.
    Leuk Lymphoma. 2015;56:774-8.
    PubMed     Text format    


  252. SCHMIDT C, Fingerle-Rowson G, Boehme A, Brendel K, et al
    Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009.
    Leuk Lymphoma. 2015;56:694-702.
    PubMed     Text format     Abstract available


  253. YOO C, Yoon DH, Yoon S, Kim S, et al
    Prognostic impact of beta(2)-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma.
    Leuk Lymphoma. 2015;56:688-93.
    PubMed     Text format     Abstract available


  254. ZHANG LN, Wang L, Fang C, Zou ZJ, et al
    The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2015;56:676-81.
    PubMed     Text format     Abstract available


  255. TSAI HT, Pfeiffer RM, Warren J, Wilson W, et al
    The effects of cardiovascular disease on the clinical outcome of elderly patients with diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2015;56:682-7.
    PubMed     Text format     Abstract available


  256. PARASOLE R, Petruzziello F, Messina C, Barisone E, et al
    Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
    Leuk Lymphoma. 2015;56:650-5.
    PubMed     Text format     Abstract available


  257. FLAMMIGER A, Bacher U, Christopeit M, Horn C, et al
    Multiparameter flow cytometry in the differential diagnosis of aberrant T-cell clones of unclear significance.
    Leuk Lymphoma. 2015;56:639-44.
    PubMed     Text format     Abstract available


    February 2015
  258. PHILLIPS AA, van Besien K
    A New "age" for High Dose Therapy and Autologous Stem Cell Transplantation.
    Leuk Lymphoma. 2015.
    PubMed     Text format    


    October 2014
  259. JAMROZIAK K, Tadmor T, Robak T, Polliack A, et al
    Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy.
    Leuk Lymphoma. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: